,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,returnOnAssets,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,8 Hillside Avenue,Suite 108,Montclair,NJ,07042,United States,973-744-1565,https://www.fluoropharma.com,Biotechnology,Healthcare,"FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.",4,"{'maxAge': 1, 'name': 'Dr. Thomas H. Tulip Ph.D.', 'age': 69, 'title': 'CEO, Pres & Director', 'yearBorn': 1953, 'fiscalYear': 2016, 'totalPay': 320000, 'exercisedValue': 0, 'unexercisedValue': 0}",1483142400,86400,4,0.0002,0.0002,0.0002,0.0002,0.0002,0.0002,0.0002,0.0002,0.0,-60.87552,400000,400000,14117,0,0,0.0,0.0,0,0,3426220,0.0002,0.0052,0.0002,0.000932,0.0,0.0,USD,5812080,0.0,30661300,34262300,0.0,0.0,-0.299,1483142400,1514678400,1483142400,-2573266,-0.0,-2.693,PNK,EQUITY,FPMI,FPMI,FLUOROPHARMA MEDICAL INC,"FluoroPharma Medical, Inc.",1305552600,America/New_York,EDT,-14400000,0.0002,none,24723,0.001,-2158517,5824558,0.002,0.005,-2.3462899,-780865,-880121,0.0,0.0,0.0,USD,
1,8 Hillside Avenue,Suite 108,Montclair,NJ,07042,United States,973-744-1565,https://www.fluoropharma.com,Biotechnology,Healthcare,"FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.",4,"{'maxAge': 1, 'name': 'Ms. Tamara  Rhein', 'age': 50, 'title': 'Chief Financial Officer', 'yearBorn': 1972, 'fiscalYear': 2016, 'totalPay': 130000, 'exercisedValue': 0, 'unexercisedValue': 0}",1483142400,86400,4,0.0002,0.0002,0.0002,0.0002,0.0002,0.0002,0.0002,0.0002,0.0,-60.87552,400000,400000,14117,0,0,0.0,0.0,0,0,3426220,0.0002,0.0052,0.0002,0.000932,0.0,0.0,USD,5812080,0.0,30661300,34262300,0.0,0.0,-0.299,1483142400,1514678400,1483142400,-2573266,-0.0,-2.693,PNK,EQUITY,FPMI,FPMI,FLUOROPHARMA MEDICAL INC,"FluoroPharma Medical, Inc.",1305552600,America/New_York,EDT,-14400000,0.0002,none,24723,0.001,-2158517,5824558,0.002,0.005,-2.3462899,-780865,-880121,0.0,0.0,0.0,USD,
2,8 Hillside Avenue,Suite 108,Montclair,NJ,07042,United States,973-744-1565,https://www.fluoropharma.com,Biotechnology,Healthcare,"FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.",4,"{'maxAge': 1, 'name': 'Mr. Edward L. Lyons Jr.', 'title': 'VP of Devel.', 'exercisedValue': 0, 'unexercisedValue': 0}",1483142400,86400,4,0.0002,0.0002,0.0002,0.0002,0.0002,0.0002,0.0002,0.0002,0.0,-60.87552,400000,400000,14117,0,0,0.0,0.0,0,0,3426220,0.0002,0.0052,0.0002,0.000932,0.0,0.0,USD,5812080,0.0,30661300,34262300,0.0,0.0,-0.299,1483142400,1514678400,1483142400,-2573266,-0.0,-2.693,PNK,EQUITY,FPMI,FPMI,FLUOROPHARMA MEDICAL INC,"FluoroPharma Medical, Inc.",1305552600,America/New_York,EDT,-14400000,0.0002,none,24723,0.001,-2158517,5824558,0.002,0.005,-2.3462899,-780865,-880121,0.0,0.0,0.0,USD,
